Drug intelligence / Profile preview

ELU116

Development stage: Preclinical
Lead developer: Eluciderm
Modality: Small Molecules
Administration: Topical

Overview

ELU116 is a preclinical-stage small molecule therapeutic developed by Eluciderm for topical application. It is specifically designed for scar reduction and the regulation of collagen production. ELU116 is part of a pipeline of compounds that leverage Eluciderm's platform for modulating the Wnt signaling pathway to stimulate the body's natural regenerative processes. By targeting these pathways, the drug aims to improve the quality of skin repair and prevent excessive fibrotic tissue formation during the healing process.

Beyond the preview

Go deeper on ELU116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELU116.

Explore the full profile